Skip to content
Clinical Trials – home
SpainBack to Spain

Clinical trials in Merida

28 clinical trials in Merida, Spain. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Merida at a glance
28
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

28 trials in Merida

Open in trial search

Study of PF-07275315 versus placebo for efficacy and safety in adults with moderate-to-severe chronic obstructive pulmonary disease (COPD)

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Pfizer Inc.

Study of AZD6793 tablets to reduce flare-ups in adults with moderate to very severe chronic obstructive pulmonary disease (COPD)

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:AstraZeneca AB

Bronchiectasis

Recruiting

Study of BI 1291583 tablets taken once daily for 76 weeks in adults with bronchiectasis

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:BI 1291583
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study on the Effectiveness and Safety of Deucravacitinib for Adults with Active Sjogren's Syndrome

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Efficacy and safety of lunsekimig in adults with inadequately controlled eosinophilic COPD: a randomized, double‑blind, placebo‑controlled trial

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Lunsekimig
  • Sponsor:Sanofi-Aventis Recherche & Developpement

A Phase 3 Study of Enpatoran to Treat Active Cutaneous Lupus in Patients With or Without Systemic Disease

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Merck Healthcare KGaA

Bronchiectasis

Recruiting

A study to evaluate the safety and effectiveness of AZD0292 in people aged 12 years and older with bronchiectasis and chronic Pseudomonas aeruginosa infection

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:AZD0292
  • Sponsor:AstraZeneca AB

Bronchiectasis

Recruiting

A study testing GSK3862995B compared to placebo for safety and effectiveness in adults aged 18 to 85 years with bronchiectasis

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:GSK3862995B
  • Sponsor:GSK PLC

Study on the Effectiveness and Safety of Dapirolizumab Pegol for Patients with Moderate to Severe Systemic Lupus Erythematosus

Registered drug
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Anhydrous Caffeine
  • Sponsor:UCB Biopharma

Study on the Long-Term Safety of Dapirolizumab Pegol for Patients with Systemic Lupus Erythematosus

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Anhydrous Caffeine
  • Sponsor:UCB Biopharma

Seasonal allergy

Not yet recruiting

Study to Find the Best Dose of Beltavac with Grass Pollen Extract for Patients with Allergic Rhinoconjunctivitis, with or without Asthma

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Placebo
  • Sponsor:Probelte Pharma S.L.
Countries:SpainSpain
  • Participants:65+ years
  • Substances:Teriparatide
  • Sponsor:Gedeon Richter Iberica S.A.

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Merida

What the registry says about research in the country

01 Autoimmune Conditions

Extensive research focusing on systemic lupus erythematosus (SLE) treatments, including trials of novel therapies like dapirolizumab pegol and GLPG3667. These studies aim to evaluate long-term safety and efficacy in managing moderate to severe disease activity.

  • Systemic Lupus Erythematosus
  • Sjögren's Syndrome
  • Systemic Sclerosis

Additional investigations include innovative treatments for diffuse cutaneous systemic sclerosis and evaluation of deucravacitinib for Sjögren's syndrome patients.

02 Respiratory Disorders

Groundbreaking trials in severe asthma management, particularly focusing on eosinophilic phenotypes. Studies include evaluation of new treatments like GSK3511294 and glycopyrronium for different age groups.

  • Severe Asthma
  • COPD
  • Bronchiectasis

Research extends to chronic obstructive pulmonary disease (COPD), testing medications like astegolimab and itepekimab for exacerbation reduction.

03 Pediatric Research

Specialized studies focusing on pediatric respiratory conditions, particularly investigating treatments for children with severe eosinophilic asthma and evaluating lung function improvements.

  • Pediatric Asthma
  • Childhood Respiratory Disorders
  • Treatment Safety in Children

Clinical trials are evaluating the safety and efficacy of medications specifically designed for young patients aged 6 to 12 years.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.